510(k) K253044
K253044 is an FDA 510(k) premarket notification submitted by Resvent Medical Technology Co., Ltd. for the device "RXiBreeze PAP System (RXiBreeze 20C)". The FDA issued a decision of Substantially Equivalent on July 23, 2026. The device falls under product code BZD (Ventilator, Non-Continuous (Respirator)), a Class II device regulated under 21 CFR 868.5905.
Clearance Details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- July 23, 2026
- Date Received
- September 22, 2025
- Clearance Type
- Traditional
- Expedited Review
- No
- Third Party Review
- No
Device Classification
- Device Name
- Ventilator, Non-Continuous (Respirator)
- Device Class
- Class II
- Regulation Number
- 868.5905
- Review Panel
- AN
- Submission Type